Kohji Nishida

Prof. Dr. Kohji Nishida


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2022 in Journal of Cataract & Refractive Surgery
Verified
Journal Article
Open access
SGSo Goto
So Goto
NMNaoyuki Maeda
Naoyuki Maeda
KOKazuhiko Ohnuma
Kazuhiko Ohnuma
TLTjundewo Lawu
Tjundewo Lawu
RKRyo Kawasaki
Ryo Kawasaki
TNToru Noda
Toru Noda
Purpose: To evaluate the performance of a new formula of intraocular lens (IOL) power calculation (the O formula) based on ray tracing without commonly used parameters, including ultrasound-compatible axial length, keratometry readings, and A-constant. Setting: Tokyo Medical Center, Tokyo, Japan. Design: Retrospective consecutive case series. Methods: 423 eyes (423 patients) implanted with a single-piece, L-loop, acrylic IOL were enrolled. All biometric data for the O formula were obtained by anterior segment swept-source optical coherence tomography (SS-OCT) and SS-OCT–based biometer. The performance of the O formula was compared with those of the Barrett Universal II (BUII) and Kane formulas at 1 month postoperatively. Statistical analysis was applied according to a heteroscedastic test with SD of prediction errors as the main parameter for formula performance. Results: The SD of the O formula (0.426) was statistically significantly lower than that of the BUII formula (0.464, P = .034) but not statistically significantly different from that of the Kane formula (0.433, P = .601). The percentages of patients with refractive prediction errors within ±0.50 diopter (D) and ±1.00 D of the O, BUII, and Kane formulas were 75.4% and 98.6%, 77.1% and 97.9%, and 76.6% and 98.1%, respectively. Conclusions: The O formula, based on ray tracing using SS-OCT–based devices, is one of the promising approaches for IOL power calculation, although additional larger scale studies are needed. It may be used as an alternative in IOL power calculation because of its independence from commonly used parameters.

19 April 2023 in Journal of Neuro-Ophthalmology
Verified
Journal Article
Open access
STShizuka Takahashi
Shizuka Takahashi
NHNoriyasu Hashida
Noriyasu Hashida
KMKazuichi Maruyama
Kazuichi Maruyama
RORina Omura
Rina Omura
RSRei Sakurai
Rei Sakurai
KNKohji Nishida
Kohji Nishida

4 January 2023 in Cureus
Verified
Journal Article
Open access
TMTamami Mimoto
Tamami Mimoto
NHNoriyasu Hashida
Noriyasu Hashida
KNKohji Nishida
Kohji Nishida
Castleman disease (CD) is a lymphoproliferative disorder and rarely affects ocular tissue. This study aimed to report a case of hypertensive choroidopathy in a patient with Castleman’s disease associated with malignant hypertension. A 39-year-old man visited his local physician with fever, systemic edema, and multiple lymphadenopathies. An inguinal lymph node biopsy indicated CD. One month after the biopsy, the patient noted a blurring of vision. At the time of the initial examination at our hospital, his best-corrected visual acuity (BCVA) was 20/20 in both eyes but there were bilateral multiple Elschnig spots and sprinter hemorrhage at the fundus. Swept-source optical coherence tomography showed intra-retinal fluid, and serous retinal detachment (SRD). Fluorescein angiography revealed multiple punctate hyper fluorescences and indocyanine green angiography showed choroidopathy with increased vascular permeability. A general examination revealed symptoms of cardiac failure and multiple lymphadenopathies. Malignant hypertension with acute glomerulonephritis was diagnosed after a renal biopsy. After antihypertensive treatment, his blood pressure (BP) improved, and the SRD and choroidopathy promptly resolved. Presently, the patient is being followed up without complications. We report a case of hypertensive choroidopathy in a patient with CD associated with malignant hypertension. As a severe elevation in BP can damage choroidal vasculature and lead to vision loss, careful observation and active treatment are necessary.

27 August 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YFYoko Fukushima
Yoko Fukushima
STShizuka Takahashi
Shizuka Takahashi
MNMachiko Nakamura
Machiko Nakamura
TITatsuya Inoue
Tatsuya Inoue
YFYusuke Fujieda
Yusuke Fujieda
KNKohji Nishida
Kohji Nishida
Background: The aim of this paper was to investigate the protein concentrations of high-temperature requirement A 1 (HTRA1) and transforming growth factor-β (TGF-β) in the vitreous humor of patients with chorioretinal vascular diseases. Methods: This study measured protein concentrations of HTRA1, TGF-β1−3, and vascular endothelial growth factor A (hereinafter called VEGF) in the vitreous humor from seven eyes of patients with chorioretinal vascular diseases (age-related macular degeneration, diabetic macular edema, and retinal vein occlusion) and six control eyes (idiopathic epiretinal membrane and macular hole). We analyzed the mutual relationship among the protein levels. Results: The protein levels of HTRA1 and VEGF were significantly increased in the chorioretinal vascular disease group compared with the control group (1.57 ± 0.79 ×10−9 mol/mL vs. 0.68 ± 0.79 ×10−9 mol/mL, p = 0.039; 3447.00 ± 3423.47 pg/mL vs. 35.33 ± 79.01 pg/mL, p = 0.046, respectively). TGF-β2 levels were not significantly different between groups (2222.71 ± 1151.25 pg/mL for the chorioretinal vascular disease group vs. 1918.83 ± 744.01 pg/mL for the control group, p = 0.62). The concentration of HTRA1 was strongly associated with TGF-β2 levels in the vitreous humor, independent of VEGF (r = 0.80, p = 0.0010). Conclusions: We revealed that vitreous HTRA1 was increased in patients with chorioretinal vascular diseases and strongly correlated with TGF-β2.

29 September 2026 in Eye & Contact Lens: Science & Clinical Practice
Verified
Journal Article
Closed access
SKShizuka Koh
Shizuka Koh
RIRyota Inoue
Ryota Inoue
Damien GatinelDamien Gatinel
Damien Gatinel
KNKohji Nishida
Kohji Nishida
Objectives: To investigate current and previous mechanical ocular stimulation behaviors beyond conventional eye rubbing in patients with keratoconus. Methods: This prospective study included Japanese outpatients with a clinical diagnosis of keratoconus in at least one eye. All participants completed a structured investigator-developed questionnaire assessing current and past mechanical ocular stimulation behaviors, followed by face-to-face physician interviews. Questionnaire items included history, reasons, duration, frequency, techniques, and anatomical sites of stimulation. Results: A total of 304 patients were included, with 91.4% reporting mechanical ocular stimulation. These behaviors were typically long-standing (75.9% >10 years) and varied widely in motivation, frequency, methods, and anatomical sites. Ocular itching was the most common trigger (75.9%), although many behaviors were unrelated to itching. Finger pulp (56.1%) and knuckles (48.6%) were commonly used, and the medial canthus was the most commonly involved site (70.1%) ( P <0.05). Pressure-related behaviors, such as eye pressing or massage during fatigue, were reported by approximately one third of patients. Conclusions: The concept of mechanical ocular stimulation provides a more comprehensive framework than eye rubbing for characterizing pressure-related behaviors in patients with keratoconus. Broader assessment of current and past behaviors may improve clinical assessment and patient counseling.